BRKR - Bruker Corp Stock Price, Fair Value and News

74.20USD-1.51 (-1.99%)Market Closed

Market Summary

USD74.20-1.51

Market Closed

-1.99%

BRKR Alerts

Big fall in earnings (Y/Y)

BRKR Stock Price

View Fullscreen

BRKR RSI Chart

BRKR Valuation

Market Cap

10.8B

Price/Earnings (Trailing)

26.85

Price/Sales (Trailing)

3.59

EV/EBITDA

17.68

Price/Free Cashflow

59.55

BRKR Price/Sales (Trailing)

BRKR Profitability

Operating Margin

50.20%

EBT Margin

16.97%

Return on Equity

28.03%

Return on Assets

8.91%

Free Cashflow Yield

1.68%

BRKR Fundamentals

BRKR Revenue

Revenue (TTM)

3.0B

Rev. Growth (Yr)

5.31%

Rev. Growth (Qtr)

-15.54%

BRKR Earnings

Earnings (TTM)

401.6M

Earnings Growth (Yr)

-33.46%

Earnings Growth (Qtr)

-75.23%

Breaking Down BRKR Revenue

Last 7 days

2.3%

Last 30 days

-15.3%

Last 90 days

-3.4%

Trailing 12 Months

0.6%

How does BRKR drawdown profile look like?

BRKR Financial Health

Current Ratio

1.81

Debt/Equity

0.95

Debt/Cashflow

0.21

BRKR Investor Care

Dividend Yield

0.27%

Dividend/Share (TTM)

0.2

Buy Backs (1Y)

0.95%

Diluted EPS (TTM)

2.74

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	3.0B	0	0	0
2023	2.6B	2.7B	2.8B	3.0B
2022	2.5B	2.5B	2.5B	2.5B
2021	2.1B	2.3B	2.4B	2.4B
2020	2.0B	2.0B	2.0B	2.0B
2019	1.9B	2.0B	2.0B	2.1B
2018	1.8B	1.8B	1.9B	1.9B
2017	1.6B	1.7B	1.7B	1.8B
2016	1.6B	1.6B	1.6B	1.6B
2015	1.7B	1.7B	1.7B	1.6B
2014	1.9B	1.9B	1.9B	1.8B
2013	1.8B	1.8B	1.8B	1.8B
2012	1.7B	1.7B	1.7B	1.8B
2011	1.4B	1.5B	1.6B	1.7B
2010	1.2B	1.2B	1.3B	1.3B
2009	0	0	0	1.1B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Bruker Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 04, 2024	requardt hermann fritz	sold	-1,350,900	90.0599	-15,000	-
Mar 04, 2024	requardt hermann fritz	acquired	330,750	22.05	15,000	-
Feb 28, 2024	busse falko	sold	-2,403,890	85.4808	-28,122	president, biospin group
Feb 28, 2024	busse falko	acquired	739,156	26.2839	28,122	president, biospin group
Feb 22, 2024	prause burkhard	sold	-1,276,070	83.3	-15,319	pres. & ceo, bruker best
Feb 22, 2024	prause burkhard	acquired	235,292	43.1728	5,450	pres. & ceo, bruker best
Jan 05, 2024	requardt hermann fritz	acquired	-	-	2,377	-
Jan 05, 2024	rosenthal bob	acquired	-	-	2,377	-
Jan 05, 2024	packer richard a	acquired	-	-	2,377	-
Jan 05, 2024	ma philip	acquired	-	-	2,377	-

Which funds bought or sold BRKR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	Clear Harbor Asset Management, LLC	new	-	201,971	201,971	0.02%
May 10, 2024	Cullen/Frost Bankers, Inc.	unchanged	-	30,690	140,910	-%
May 10, 2024	VisionPoint Advisory Group, LLC	reduced	-31.28	-5,079	36,731	0.01%
May 10, 2024	DIMENSIONAL FUND ADVISORS LP	added	0.42	24,417,800	110,448,000	0.03%
May 10, 2024	Castleview Partners, LLC	added	28.00	2,338	6,012	-%
May 10, 2024	ACADIAN ASSET MANAGEMENT LLC	reduced	-90.82	-619,000	82,000	-%
May 10, 2024	Vontobel Holding Ltd.	added	0.27	83,017	377,451	-%
May 10, 2024	LPL Financial LLC	added	8.11	3,823,540	13,829,600	0.01%
May 10, 2024	PRINCIPAL SECURITIES, INC.	reduced	-3.5	9,804	51,761	-%
May 10, 2024	VANGUARD GROUP INC	reduced	-0.37	199,075,000	926,291,000	0.02%

Are Funds Buying or Selling BRKR?

Are funds buying BRKR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BRKR

No. of Funds

BRKR Alerts

Big fall in earnings (Y/Y)

Unveiling Bruker Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	t. rowe price investment management, inc.	9.5%	13,192,344	SC 13G/A
Feb 13, 2024	vanguard group inc	7.15%	9,896,786	SC 13G/A
Feb 09, 2024	massachusetts financial services co /ma/	5.8%	8,080,071	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 26, 2024	blackrock inc.	7.1%	9,822,776	SC 13G/A
Feb 14, 2023	t. rowe price investment management, inc.	11.1%	16,368,144	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	7.51%	11,045,016	SC 13G/A
Feb 08, 2023	massachusetts financial services co /ma/	5.1%	7,513,039	SC 13G
Jan 31, 2023	blackrock inc.	7.6%	11,118,621	SC 13G/A

Recent SEC filings of Bruker Corp

View All Filings

Date Filed	Form Type	Document
May 10, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
May 02, 2024	8-K	Current Report
Apr 22, 2024	8-K	Current Report
Apr 19, 2024	DEF 14A	DEF 14A
Apr 19, 2024	DEFA14A	DEFA14A
Apr 02, 2024	8-K	Current Report
Mar 12, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 04, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Bruker Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	182.3B	40.3B	-3.98%	-5.18%	32.4	4.52	-2.84%	-3.08%
BDX	68.5B	19.7B	0.76%	-6.16%	51.38	3.47	4.82%	-17.56%
ALGN	20.5B	3.9B	-13.41%	-7.14%	44.42	5.24	5.72%	46.72%
BAX	18.0B	14.9B	-12.17%	-16.60%	6.81	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	7.78%	22.43%	31.32	2.77	6.16%	35.06%
HSIC	9.4B	12.5B	3.00%	-4.30%	24.14	0.75	-0.61%	-18.83%
BIO	8.1B	2.6B	-4.97%	-23.36%	-25.25	3.13	-6.25%	-68.62%
XRAY	5.8B	3.9B	-10.03%	-31.12%	-62.53	1.48	0.23%	91.03%
AXNX	3.4B	387.1M	-0.36%	24.53%	-215.69	8.88	30.82%	65.57%
PDCO	2.3B	6.6B	0.43%	-3.80%	11.84	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-3.35%	-10.28%	-1.82	0.39	7.94%	-1661.78%
ANIK	379.6M	169.3M	2.40%	1.75%	-4.94	2.24	7.49%	-244.90%
ANGO	245.1M	324.0M	-3.92%	-34.26%	-1.27	0.76	-3.19%	-337.41%
APYX	50.6M	50.5M	-	-72.76%	-2.22	1	14.25%	-10.06%
AEMD	2.6M	3.7M	-35.10%	206.25%	-0.21	0.68	5.77%	8.23%

Bruker Corp News

Latest updates

Bruker Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-15.5%	722	855	743	682	685	708	639	588	595	684	609	571	555	628	511	425	424	600	521	490	461
Cost Of Revenue	-13.0%	369	424	360	341	326	343	304	290	289	342	300	290	276	315	263	238	232	304	267	260	247
Gross Profit	-18.0%	353	430	383	341	360	366	335	298	306	342	309	281	279	313	248	186	192	296	254	230	215
Operating Expenses	-11.9%	288	327	258	254	237	235	204	224	210	216	196	195	190	200	167	148	176	179	166	177	173
S&GA Expenses	-7.5%	195	211	178	178	163	165	145	152	146	153	141	135	132	130	115	102	121	130	125	125	120
R&D Expenses	-2.0%	82.00	84.00	71.00	71.00	69.00	64.00	56.00	60.00	57.00	58.00	52.00	56.00	55.00	57.00	48.00	44.00	49.00	47.00	46.00	49.00	46.00
EBITDA Margin	-4.8%	0.22*	0.23*	0.20*	0.20*	0.21*	0.21*	0.21*	0.20*	0.21*	0.21*	0.21*	0.20*	-	-	-	-	-	-	-	-	-
Income Taxes	-46.6%	20.00	37.00	31.00	20.00	30.00	23.00	41.00	20.00	32.00	44.00	21.00	21.00	28.00	34.00	20.00	7.00	3.00	42.00	22.00	11.00	8.00
Earnings Before Taxes	-70.3%	72.00	241	119	78.00	107	121	129	70.00	94.00	120	109	80.00	85.00	106	75.00	31.00	14.00	111	83.00	48.00	38.00
EBT Margin	-7.6%	0.17*	0.18*	0.15*	0.16*	0.16*	0.16*	0.16*	0.16*	0.16*	0.16*	0.16*	0.15*	-	-	-	-	-	-	-	-	-
Net Income	-75.2%	51.00	206	88.00	57.00	77.00	97.00	88.00	50.00	62.00	76.00	87.00	58.00	57.00	69.00	54.00	24.00	11.00	69.00	61.00	37.00	31.00
Net Income Margin	-7.1%	0.13*	0.14*	0.11*	0.12*	0.12*	0.12*	0.11*	0.11*	0.11*	0.11*	0.11*	0.10*	-	-	-	-	-	-	-	-	-
Free Cashflow	-99.8%	0.00	174	17.00	-10.50	63.00	137	12.00	-62.30	59.00	110	8.00	-0.70	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	6.0%	4,506	4,250	3,820	3,857	3,764	3,612	3,337	3,385	3,551	3,650	3,128	3,087	3,035	3,049	2,879	2,943	2,962	2,772	2,352	2,350	2,243
Current Assets	-1.1%	2,140	2,164	2,029	2,183	2,133	2,113	2,037	2,088	2,251	2,472	1,989	1,968	1,946	1,925	1,826	1,957	1,990	1,796	1,434	1,406	1,344
Cash Equivalents	-29.7%	343	488	364	575	598	646	629	726	820	1,072	577	612	700	686	571	750	799	682	300	287	303
Inventory	9.5%	1,061	968	916	915	859	800	750	759	740	710	733	730	701	692	696	665	626	577	587	595	542
Net PPE	-2.3%	586	600	527	523	511	487	422	395	404	406	389	398	384	396	355	336	319	306	278	282	268
Goodwill	29.1%	752	583	561	558	527	458	382	396	384	340	324	315	313	320	313	295	290	293	282	285	6.00
Liabilities	7.7%	3,056	2,837	-	-	-	2,480	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current Liabilities	-1.6%	1,183	1,202	1,072	1,051	1,049	914	865	818	881	939	921	955	944	792	683	750	766	646	643	641	633
Long Term Debt	17.0%	1,357	1,160	1,099	1,123	1,109	1,201	1,137	1,171	1,205	1,222	718	721	716	842	828	924	915	813	519	494	332
LT Debt, Non Current	-100.0%	-	1,160	1,099	1,123	1,109	1,201	1,137	1,171	1,205	1,222	718	721	716	842	828	924	915	813	519	494	-
Shareholder's Equity	4.0%	1,433	1,377	1,209	1,251	1,199	1,114	948	984	1,031	1,085	1,090	1,015	982	974	963	907	925	917	855	870	922
Retained Earnings	1.9%	2,367	2,324	-	-	-	1,926	-	-	-	1,660	-	-	-	1,407	-	-	-	1,275	-	-	-
Additional Paid-In Capital	2.9%	291	283	-	-	-	256	-	-	-	238	-	-	-	216	-	-	-	200	-	-	-
Shares Outstanding	0.1%	145	145	146	147	147	147	147	148	149	151	152	151	-	-	-	-	-	-	-	-	-
Minority Interest	1.1%	18.00	17.00	18.00	20.00	19.00	12.00	11.00	14.00	14.00	14.00	14.00	13.00	14.00	13.00	11.00	9.00	9.00	10.00	10.00	9.00	8.00
Float	-	-	-	-	6,099	-	-	-	4,001	-	-	-	4,040	-	-	-	2,173	-	-	-	5,068	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-89.4%	21,800	205,500	44,100	13,000	87,500	171,500	69,500	-44,400	77,800	138,600	23,900	21,900	98,000	203,000	82,400	11,800	35,000	136,200	52,400	10,600	14,200
Share Based Compensation	-14.5%	5,300	6,200	5,700	5,600	6,500	4,700	5,300	9,700	8,000	5,300	4,200	3,900	3,800	5,100	4,500	3,100	3,300	-500	4,000	3,000	3,100
Cashflow From Investing	-726.6%	-304,200	-36,800	-155,000	-26,000	-108,200	-149,300	-57,600	57,100	-101,800	-48,600	-48,400	-71,400	-24,000	-28,800	-48,200	-15,100	-100,600	-39,200	-12,600	-79,900	-26,700
Cashflow From Financing	353.3%	151,700	-59,900	-92,500	-10,300	-30,700	-36,100	-82,000	-79,800	-217,400	404,300	-2,600	-44,900	-38,100	-74,300	-225,500	-53,100	191,300	277,900	-19,500	50,400	-8,800
Dividend Payments	0%	7,300	7,300	7,400	7,300	7,400	7,400	7,400	7,500	7,500	6,000	6,100	6,000	6,100	6,100	6,200	6,100	6,200	6,200	6,200	6,300	6,300
Buy Backs	-100.0%	-	50,400	80,300	100	22,300	25,550	72,400	60,300	105,600	82,200	-	38,300	32,800	68,800	5,000	50,000	-	-	42,300	100,000	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BRKR Income Statement

2024-03-31

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total revenue	$ 721.7	$ 685.3
Total cost of revenue	368.9	325.6
Gross profit	352.8	359.7
Operating expenses:
Selling, general and administrative	195.3	162.7
Research and development	81.8	69.0
Other charges, net	10.9	5.3
Total operating expenses	288.0	237.0
Operating income	64.8	122.7
Interest and other income (expense), net	6.8	(16.1)
Income before income taxes, equity in income of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries	71.6	106.6
Income tax provision	19.8	29.9
Equity in income of unconsolidated investees, net of tax	0.2	0.7
Net income	52.0	77.4
Net income attributable to noncontrolling interests in consolidated subsidiaries	1.1	0.9
Net income attributable to Bruker Corporation	$ 50.9	$ 76.5
Net income per common share attributable to Bruker Corporation shareholders:
Basic	$ 0.35	$ 0.52
Diluted	$ 0.35	$ 0.52
Weighted average common shares outstanding:
Basic	145.2	146.8
Diluted	145.9	147.6
Product
Total revenue	$ 586.9	$ 567.1
Total cost of revenue	291.7	257.2
Other
Total revenue	134.8	118.2
Total cost of revenue	$ 77.2	$ 68.4

BRKR Balance Sheet

2024-03-31

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 340.1	$ 488.3
Accounts receivable, net	475.4	492.0
Inventories	1,060.5	968.3
Other current assets	264.4	215.6
Total current assets	2,140.4	2,164.2
Property, plant and equipment, net	586.1	599.7
Goodwill	751.9	582.6
Intangible assets, net	449.2	330.5
Operating lease assets	105.1	91.7
Deferred tax assets	280.1	297.2
Other long-term assets	193.6	184.0
Total assets	4,506.4	4,249.9
Current liabilities:
Current portion of long-term debt	21.2	121.2
Accounts payable	199.1	202.7
Deferred revenue and customer advances	485.2	400.0
Other current liabilities	477.0	478.2
Total current liabilities	1,182.5	1,202.1
Long-term debt	1,357.3	1,160.3
Long-term deferred revenue and customer advances	105.6	91.5
Deferred tax liabilities	81.8	67.7
Operating lease liabilities	85.7	74.8
Accrued pension	76.0	76.6
Other long-term liabilities	166.7	163.6
Total liabilities	3,055.6	2,836.6
Commitments and contingencies (Note 16)
Redeemable noncontrolling interests	17.9	18.7
Shareholders' equity:
Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding	0.0	0.0
Common stock, $0.01 par value 260,000,000 shares authorized, 176,113,521 and 175,943,705 shares issued and 145,334,642 and 145,164,826 shares outstanding at March 31, 2024 and December 31, 2023, respectively.	1.7	1.7
Treasury stock, at cost, 30,778,879 shares at March 31, 2024, and December 31, 2023, respectively	(1,237.2)	(1,237.2)
Additional paid-in capital	291.1	282.9
Retained earnings	2,367.4	2,323.8
Accumulated other comprehensive (loss) income, net of tax	(7.7)	6.0
Total shareholders' equity attributable to Bruker Corporation	1,415.3	1,377.2
Noncontrolling interests in consolidated subsidiaries	17.6	17.4
Total shareholders' equity	1,432.9	1,394.6
Total liabilities, redeemable noncontrolling interests and shareholders' equity	$ 4,506.4	$ 4,249.9

About Bruker Corp

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

CEO	Dr. Frank H. Laukien Ph.D.
WEBSITE	bruker.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	8525

Bruker Corp Frequently Asked Questions

What is the ticker symbol for Bruker Corp? What does BRKR stand for in stocks?

BRKR is the stock ticker symbol of Bruker Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bruker Corp (BRKR)?

As of Mon May 13 2024, market cap of Bruker Corp is 10.78 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BRKR stock?

You can check BRKR's fair value in chart for subscribers.

What is the fair value of BRKR stock?

You can check BRKR's fair value in chart for subscribers. The fair value of Bruker Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bruker Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BRKR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bruker Corp a good stock to buy?

The fair value guage provides a quick view whether BRKR is over valued or under valued. Whether Bruker Corp is cheap or expensive depends on the assumptions which impact Bruker Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BRKR.

What is Bruker Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, BRKR's PE ratio (Price to Earnings) is 26.85 and Price to Sales (PS) ratio is 3.59. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BRKR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Bruker Corp's stock?

In the past 10 years, Bruker Corp has provided 0.142 (multiply by 100 for percentage) rate of return.